Last $10.61 USD
Change Today -0.08 / -0.75%
Volume 1.7M
INO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/27/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

660 West Germantown Pike

Suite 100

Plymouth Meeting, PA 19462

United States

Phone: 267-440-4200

Fax: 267-440-4242

Inovio Pharmaceuticals, Inc., a bio-pharmaceutical company, develops active DNA immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The company’s DNA-based immunotherapies, in combination with its proprietary electroporation delivery devices, are intended to generate immune responses, in particular T cells, in the body to fight target diseases. In 2014, the company reported that in a controlled phase II clinical study that the company generated functional antigen-specific T cells that correlated to clinically relevant efficacy against human papillomavirus (HPV)-associated cervical precancer. The company plans to launch a phase III study of this product in 2016 and is advancing multiple cancer clinical studies. The company’s novel SynCon immunotherapy design has shown the ability to help break the immune system’s tolerance of cancerous cells. The company’s SynCon product design approach is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers (cervical, head and neck, and anal), prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza, Ebola, MERS (Middle East Respiratory Syndrome) and Zika virus. The company’s partners and collaborators include MedImmune, LLC; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche); University of Pennsylvania; GeneOne Life Science Inc. (GeneOne); Drexel University; National Microbiology Laboratory of the Public Health Agency of Canada; National Institute of Allergy and Infectious Diseases; the United States Military HIV Research Program; the U.S. Army Medical Research Institute of Infectious Diseases; HIV Vaccines Trial Network; and Defense Advanced Research Projects Agency (DARPA). Immunotherapy Products and Product Development The company’s primary focus is to independently and/or in partnerships advance the products developed from its integrated platform consisting of its SynCon immunotherapy and CELLECTRA electroporation technologies. The company is developing various DNA-based immunotherapies for the prevention or treatment of cancer and chronic infectious diseases. Cancer Vaccines/Immunotherapies HPV Immunotherapy-VGX-3100 Late Stage Cervical Dysplasia (CIN 2/3) The company’s VGX-3100 is an immunotherapy designed to increase immune responses (humoral and cell mediated) against the E6 and E7 antigens of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into pre-cancerous and cancerous cells. The company completed a phase I study of its cervical precancer immunotherapy (VGX-3100) in 2010. This dose escalation study tested the safety and immunogenicity of VGX-3100 in women previously treated for moderate or severe cervical intraepithelial neoplasia (CIN 2/3), a high grade premalignant lesion that is a precursor to cervical cancer. Based on the phase II results, the company has stated its intention to advance VGX-3100 into a phase III study in 2016. The company intends to obtain alignment with the FDA and various global regulatory agencies on the details of the pivotal phase III program to support an indication in CIN 2/3. The company has conducted additional market research with physicians and patients that have further characterized the unmet medical needs relating to the treatment of high grade cervical dysplasia (CIN 2/3). VGX-3100 has the potential to be a less-invasive first-line treatment option that spares women from the anxiety of surgery and the risks it poses to their reproductive health. The company also plans to expand VGX-3100 to treat other dysplasia conditions caused by HPV infections, such as vulvar and anal intraepithelial neoplasias. HPV Immunotherapy-INO-3112 (VGX-3100 +DNA-Based IL-12 Cytokine INO-9012) Head and Neck Cancer and Cervical Cancer In 2014,

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $10.61 USD -0.08

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aduro Biotech Inc $11.71 USD +0.34
Dynavax Technologies Corp $15.85 USD 0.00
Novavax Inc $5.86 USD +0.24
Peregrine Pharmaceuticals Inc $0.41 USD +0.0044
ZIOPHARM Oncology Inc $7.39 USD +0.33
View Industry Companies
 

Industry Analysis

INO

Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.6x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact INOVIO PHARMACEUTICALS INC, please visit www.inovio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.